ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Novartis is set to buy the German drugmaker MorphoSys for $3.0 billion. MorphoSys has two wholly owned programs. One is pelabresib, which is designed to block bromodomain and extraterminal domain (BET) proteins as a treatment for myelofibrosis and essential thrombocythemia. Pelabresib is up for review by the US Food and Drug Administration this year. The other is tulmimetostat, which targets the genes EZH1 and EZH2 to treat multiple types of cancer.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter